Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy

García‐Ropero, Álvaro; Santos‐Gallego, Carlos G.; Vargas-Delgado, Ariana P.; Requena-Ibáñez, Juan Antonio; Picatoste, Belén; Ishikawa, Kiyotake; Sanz, Javier; Tuñón, José; Badimón, Juan J.

doi:10.1080/14779072.2020.1802247

Cited by 9 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Garcia-Ropero et al [ 37 ] found that empagliflozin improved myocardial deformation estimated by speckle tracking echocardiography in an ischemic non-diabetic porcine model. However, clinical studies of the effects of SGLT2 inhibitors on myocardial deformation parameters are lacking.…”

Section: Discussionmentioning

confidence: 99%

Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

Gamaza-Chulián

Díaz‐Retamino

González-Testón

et al. 2021

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) lower cardiovascular events in type 2 diabetes mellitus (T2DM) patients, although the mechanisms underlying these benefits are not clearly understood. Our aim was to study the effects of SGLT2i on left ventricular remodelling and longitudinal strain. Methods Between November 2019 and April 2020, we included 52 patients with T2DM ≥ 18 years old, with HbA1c between 6.5 and 10.0%, and estimated glomerular filtration ≥ 45 ml/min/1.73 m2. Patients were classified into SGLT2i group and control group, according to prescribed treatment by their referring physician. Conventional and speckle tracking echocardiography were performed by blinded sonographers, at baseline and after 6 months of treatment. Results Among the 52 included patients (44% females, mean age 66.8 ± 8.6 years, mean HbA1c was 7.40 ± 0.7%), 30 patients were prescribed SGLT2i and 22 patients were classified as control group. Mean change in indexed left ventricular mass (LVM) was − 0.85 ± 3.31 g/m2 (p = 0.003) in the SGLT2i group, and + 2.34 ± 4.13 g/m2 (p = 0.58) in the control group. Absolute value of Global Longitudinal Strain (GLS) increased by a mean of 1.29 ± 0.47 (p = 0.011) in the SGLT2i group, and 0.40 ± 0.62 (p = 0.34) in the control group. We did not find correlations between changes in LVM and GLS, and other variables like change in HbA1c. Conclusions Among patients with T2DM, SGLT2i were associated with a significant reduction in indexed LVM and a significant increment in longitudinal strain measured by speckle tracking echocardiography, which may explain in part the clinical benefits found in clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

Gamaza-Chulián

Díaz‐Retamino

González-Testón

et al. 2021

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…Studies from us and from others have indicated that oral administration of SGLT2is empagliflozin in small and large animal models of HFrEF improved systolic function, increased circulating ketone levels, associated with enhanced cardiac ketone oxidation, and increased cardiac ATP production [93,94]. Furthermore, chronic oral treatment with SGLT2is empagliflozin improved diastolic function and cardiac strain parameters in a large animal model of HFrEF [95,96]. In a small animal model of HFpEF, oral administration of SGLT2is for 30 days improved HFpEF phenotypes [74].…”

Section: Sodium-glucose Co-transporter 2 Inhibitorsmentioning

confidence: 93%

Ketone bodies for the failing heart: fuels that can fix the engine?

Yurista

Nguyen

Rosenzweig

et al. 2021

Trends in Endocrinology & Metabolism

View full text Add to dashboard Cite

“…Garcia-Ropero et al [37] found that empagli ozin improved myocardial deformation estimated by speckle tracking echocardiography in an ischemic non-diabetic porcine model. However, clinical studies of the effects of SGLT2 inhibitors on myocardial deformation parameters are lacking.…”

Section: Discussionmentioning

confidence: 99%

Effect of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Left Ventricular Remodelling and Longitudinal Strain: A Prospective Observational Study

Gamaza-Chulián

Díaz‐Retamino

González-Testón

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) lower cardiovascular events in type 2 diabetes mellitus (T2DM) patients, although the mechanisms underlying these benefits are not clearly understood. Our aim was to study the effects of SGLT2i on left ventricular remodelling and longitudinal strain.Methods: Between November 2019 and April 2020, we included 52 patients with T2DM ≥18 years old, with HbA1c between 6.5% and 10.0%, and estimated glomerular filtration ≥45 ml/min/1.73 m2. Patients were classified into SGLT2i group and control group, according to prescribed treatment by their referring physician. Conventional and speckle tracking echocardiography were performed by blinded sonographers, at baseline and after 6 months of treatment.Results: Among the 52 included patients (44% females, mean age 66.8±8.6 years, mean HbA1c was 7.40±0.7%), 30 patients were prescribed SGLT2i and 22 patients were classified as control group. Mean change in indexed left ventricular mass (LVM) was -10.85±3.31 g/m2 (p=0.003) in the SGLT2i group, and +2.34±4.13 g/m2 (p=0.58) in the control group. Absolute value of Global Longitudinal Strain (GLS) increased by a mean of 1.29±0.47 (p=0.011) in the SGLT2i group, and 0.40±0.62 (p=0.34) in the control group. We did not find correlations between changes in LVM and GLS, and other variables like change in HbA1c.Conclusions: Among patients with T2DM, SGLT2i were associated with a significant reduction in indexed LVM and a significant increment in longitudinal strain measured by speckle tracking echocardiography, which may explain in part the clinical benefits found in clinical trials.

show abstract

Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy

Cited by 9 publications

References 31 publications

Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

Ketone bodies for the failing heart: fuels that can fix the engine?

Effect of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Left Ventricular Remodelling and Longitudinal Strain: A Prospective Observational Study

Contact Info

Product

Resources

About